India has a strong presence in the pharmaceutical industry’s CDMO (contract development and manufacturing organization) segment. Since India offers world-class quality pharma products at a low price, contract manufacturing is among the fastest expanding areas of the pharmaceutical business. Contract manufacturing for pharmaceuticals requires innovative technologies to keep up with changing market trends. Today, the emphasis is on building resilience in supply chains with multiple facilities across locations to meet the rising and unprecedented demand. According to MarketsandMarkets, the worldwide pharmaceutical contract development and manufacturing market is expected to grow at a CAGR of 7.7%, from USD 100.7 billion in 2020 to USD 146.1 billion in 2025.
The ever-expanding demand for generics increased pharmaceutical R&D spending, and CDMO investments in sophisticated production methods are some of the factors driving the growth of CDMOs today.
As a contract development and manufacturing organization (CDMO) supporting key players in the pharmaceutical industry, Ikris Pharma Network (IPN) has prepared for the future by implementing this guidance. Our new multi-product, large-scale fill/finish facility was designed from the ground up with safety, quality, and flexibility top of our minds. By investing in best-in-class equipment supported by the latest technology and designing a facility with superior environmental, health and safety, engineering, and cross-contamination controls, Ikris can support the varied needs of current and prospective clients now and in the future.
As the entire pharmaceutical manufacturing industry continues to shoulder immense pressure to be more cost-effective and reduce timelines for life-saving medicines, dynamic multi-product facilities, and equipment design will only grow in prominence. Flexible equipment supported by modern facility design, along with proven processes and controls, reduce risk and can ultimately help eliminate the threat of cross-contamination. With demand growing daily, pharmaceutical companies should take decisive action today to better prepare for tomorrow by investing significant capital in facility and equipment design modernization.
